RE:RE:RE:Slowdown in Covid-19 sales will further move Pfizer to M&AThe Global consulting companies PwC and EY have issued reports that Big Pharma has over $US1.25 Trillion in firepower and that Big Pharma's "sweet-spot" for small- medium size company M&A deals is between US$5 Billion and US$15 Billion ... so therefore a north of US$ 8 Billion deal expectation for the acquisition of ONCY is comfortably within the parameters of of Big Pharma's "sweet-spot", particularly since ONCY's pelareorep is a Platform Technology that can be used in multiple cancers in combination with multiple existing immuno-oncology therapies.